The synergistic function of long and short forms of β4GalT1 in p53-mediated drug resistance in bladder cancer cells

Li, Hongjiao; Yang, Fenfang; Chang, Kaijing; Yu, Xuefeng; Guan, Feng; Li, Xiang

doi:10.1016/j.bbamcr.2022.119409

Cited by 4 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has also been found that the total mRNA level of β1,4-galactosyltransferase-1 (β4GalT1), an enzyme that catalyzes the transfer of galactose from UDP-Gal to GlcNAc and forms the poly-N-acetyllactosamine structure, was significantly higher in BC tissues than in normal ones [153]. Moreover, the level of upregulated expression of a long-form of β4GalT1 (β4GalT1-L) was higher than that of short-form β4GalT1 (β4GalT1-S) in BC cells.…”

Section: The Role Of Core 2 Structures In Bladder Cancermentioning

confidence: 99%

Altered Glycosylation in Progression and Management of Bladder Cancer

2023

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most common malignancy worldwide, with an estimated 573,000 new cases and 213,000 deaths in 2020. Available therapeutic approaches are still unable to reduce the incidence of BC metastasis and the high mortality rates of BC patients. Therefore, there is a need to deepen our understanding of the molecular mechanisms underlying BC progression to develop new diagnostic and therapeutic tools. One such mechanism is protein glycosylation. Numerous studies reported changes in glycan biosynthesis during neoplastic transformation, resulting in the appearance of the so-called tumor-associated carbohydrate antigens (TACAs) on the cell surface. TACAs affect a wide range of key biological processes, including tumor cell survival and proliferation, invasion and metastasis, induction of chronic inflammation, angiogenesis, immune evasion, and insensitivity to apoptosis. The purpose of this review is to summarize the current information on how altered glycosylation of bladder cancer cells promotes disease progression and to present the potential use of glycans for diagnostic and therapeutic purposes.

show abstract

Section: The Role Of Core 2 Structures In Bladder Cancermentioning

confidence: 99%

Altered Glycosylation in Progression and Management of Bladder Cancer

2023

View full text Add to dashboard Cite

show abstract

LacNAc modification in bone marrow stromal cells enhances resistance of myelodysplastic syndrome cells to chemotherapeutic drugs

Li,

Ren,

Pang

et al. 2023

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

View full text Add to dashboard Cite

The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy

Wang

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Bladder cancer is one of the common malignant urothelial tumors. Post-translational modification (PTMs), including ubiquitination, acetylation, methylation, and phosphorylation, have been revealed to participate in bladder cancer initiation and progression. Ubiquitination is the common PTM, which is conducted by E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin-protein ligase. E3 ubiquitin ligases play a key role in bladder oncogenesis and progression and drug resistance in bladder cancer. Therefore, in this review, we summarize current knowledge regarding the functions of E3 ubiquitin ligases in bladder cancer development. Moreover, we provide the evidence of E3 ubiquitin ligases in regulation of immunotherapy in bladder cancer. Furthermore, we mention the multiple compounds that target E3 ubiquitin ligases to improve the therapy efficacy of bladder cancer. We hope our review can stimulate researchers and clinicians to investigate whether and how targeting E3 ubiquitin ligases acts a novel strategy for bladder cancer therapy.

show abstract

The synergistic function of long and short forms of β4GalT1 in p53-mediated drug resistance in bladder cancer cells

Cited by 4 publications

References 36 publications

Altered Glycosylation in Progression and Management of Bladder Cancer

Altered Glycosylation in Progression and Management of Bladder Cancer

LacNAc modification in bone marrow stromal cells enhances resistance of myelodysplastic syndrome cells to chemotherapeutic drugs

The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy

Contact Info

Product

Resources

About